X
By submitting this form, you agree to be contacted regarding your request, and you are confirming you agree to our Privacy Policy. Form will be automatically forwarded to the independent patient information center of International Virotherapy Center.
Treatment & Availability
RIGVIR® is registered by the State Agency of Medicines of the Republic of Latvia, becoming the first approved oncolytic virotherapy medication.
Rigvir Group E-mail: pr@rigvir.com
